Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 3
1991 1
1993 2
1994 2
1995 1
1996 4
1997 2
1998 2
1999 5
2000 21
2001 46
2002 54
2003 62
2004 76
2005 72
2006 89
2007 72
2008 66
2009 64
2010 71
2011 72
2012 51
2013 64
2014 62
2015 63
2016 63
2017 63
2018 59
2019 57
2020 80
2021 80
2022 84
2023 81
2024 77
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,537 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. ...The ChE-Is currently available in the market are donepezil, rivastigmine and …
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of co …
Alzheimer's disease.
Blennow K, de Leon MJ, Zetterberg H. Blennow K, et al. Lancet. 2006 Jul 29;368(9533):387-403. doi: 10.1016/S0140-6736(06)69113-7. Lancet. 2006. PMID: 16876668 Review.
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease--ie, plaques, composed of amyloid beta (Abeta), and tangles, composed of hyper …
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the …
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Tan CC, et al. J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. J Alzheimers Dis. 2014. PMID: 24662102 Review.
BACKGROUND: The role of currently available drugs for Alzheimer's disease (AD) has been controversial, with some national formularies restricting their use, and health economists questioning whether the small clinical effects are economically worthwhile. OBJE …
BACKGROUND: The role of currently available drugs for Alzheimer's disease (AD) has been controversial, with some nation …
Cholinesterase inhibitors for Alzheimer's disease.
Birks J. Birks J. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593. Cochrane Database Syst Rev. 2006. PMID: 16437532 Free PMC article. Review.
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). ...OBJECTIVES: To assess the …
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of eac …
Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
Lim AWY, Schneider L, Loy C. Lim AWY, et al. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4. Cochrane Database Syst Rev. 2024. PMID: 39498781
BACKGROUND: Dementia leads to progressive cognitive decline, and represents a significant health and societal burden. Its prevalence is growing, with Alzheimer's disease as the leading cause. There is no cure for Alzheimer's disease, but …
BACKGROUND: Dementia leads to progressive cognitive decline, and represents a significant health and societal burden. Its prevalence is grow …
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Hansen RA, et al. Clin Interv Aging. 2008;3(2):211-25. Clin Interv Aging. 2008. PMID: 18686744 Free PMC article. Review.
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. ...Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and ri …
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, a …
Galantamine for Alzheimer's disease.
Prvulovic D, Hampel H, Pantel J. Prvulovic D, et al. Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):345-54. doi: 10.1517/17425251003592137. Expert Opin Drug Metab Toxicol. 2010. PMID: 20113148 Review.
IMPORTANCE OF THE FIELD: Alzheimer's disease (AD) is the most frequent, age-related neurodegenerative disorder and is characterized by progressive deterioration of cognition and global functioning. ...As long as no other drug therapies with comparable or bett …
IMPORTANCE OF THE FIELD: Alzheimer's disease (AD) is the most frequent, age-related neurodegenerative disorder and is c …
Galantamine for Alzheimer's disease.
Loy C, Schneider L. Loy C, et al. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. doi: 10.1002/14651858.CD001747.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. doi: 10.1002/14651858.CD001747.pub3. PMID: 15495017 Updated. Review.
BACKGROUND: Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. OBJECTIVES: To assess the clinical effects of galantamine in patients with probable or possible Alzheimer's disease (AD), and potential moderators …
BACKGROUND: Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. OBJECTIVES: To assess the clinical …
Galantamine for Alzheimer's disease.
Olin J, Schneider L. Olin J, et al. Cochrane Database Syst Rev. 2002;(3):CD001747. doi: 10.1002/14651858.CD001747. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. doi: 10.1002/14651858.CD001747.pub2. PMID: 12137632 Updated. Review.
A small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease (AD), and recently several multicentre clinical trials have been published with positive findings. ...Intention-to-treat and observed cases data we …
A small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease (AD), a …
Galantamine for Alzheimer's disease.
Olin J, Schneider L. Olin J, et al. Cochrane Database Syst Rev. 2001;(4):CD001747. doi: 10.1002/14651858.CD001747. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747. doi: 10.1002/14651858.CD001747. PMID: 11687119 Updated. Review.
A small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease (AD), and recently several multicenter clinical trials have been published with positive findings. ...Intention-to-treat and observed cases data we …
A small number of early studies showed mild cognitive and global benefits for patients with Alzheimer's disease (AD), a …
1,537 results